MedTrace Logo

Effect of Bifidobacterium Lactis HN019 on Colonic Transit Time and Digestive Symptoms

NCT01171014 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2010-07-28

No results posted yet for this study

Summary

The purpose of this study was to investigate the dose response effect of Bifidobacterium lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms.

Conditions

  • Gastrointestinal Symptoms

Interventions

DIETARY_SUPPLEMENT

Bifidobacterium lactis HN019

Bifidobacterium lactis HN019, 10 billion cfu/day, once a day for 14 days

DIETARY_SUPPLEMENT

Bifidobacterium lactis HN019

Bifidobacterium lactis HN019, 1 billion cfu/day, once a day for 14 days

DIETARY_SUPPLEMENT

Placebo

Placebo, once a day for 14 days

Sponsors & Collaborators

  • Danisco

    collaborator INDUSTRY

  • Sprim Advanced Life Sciences

    collaborator OTHER

  • Fonterra Research Centre

    lead INDUSTRY

Principal Investigators

  • Philip Waller, MD · Accurate Clinical Research, Houston, TX

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2009-12-31
Completion
2009-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01171014 on ClinicalTrials.gov